FILE:LH/LH-8K-20091110165956.txt.gz
EVENTS:	Regulation FD Disclosure
TEXT:
ITEM: Regulation FD Disclosure
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01. Regulation FD Disclosure
Summary information of the Company in connection with the presentation at the Credit Suisse 18th Annual Healthcare Conference on November 13, 2009.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Phoenix, AZ
November 13, 2009
Credit Suisse 18
th
Annual
Healthcare Conference
2
This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors.  
Actual results could differ materially from those suggested by these forward-looking statements.   Further information on potential factors that could affect the Company's financial results is included in the Company's Form 10-K for the year ended December 31, 2008, and subsequent SEC filings.
Forward Looking Statement
Introduction
3
Leading National
Lab Provider
Fastest growing national lab
$52 Billion market
Clinical, Anatomic and Genomic Testing
Serving clients in all 50 states and Canada
Foremost clinical trials testing business
Introduction
4
Valuable Service
  Small component of total cost
    influences large percentage
    of clinical decisions
  Screening, early detection,
    and monitoring reduce
    downstream costs
  Companion diagnostics
    improve drug efficacy and
    reduce adverse drug effects
  
Attractive Market
5
Attractive Market
6
Growth Drivers  
  Aging population
  Industry consolidation
  Advances in genomics
  Pharmacogenomics /
    companion diagnostics
  Cost pressures   
Source:   CDC National Ambulatory Medical Care Survey and Company Estimates
Attractive Market
7
Opportunity to
Take Share  
  5,100 independent labs
  High cost competitors
Attractive Market
Diversified Payor Mix
  No customer > 9% of revenue
  Limited government exposure
8
Attractive Market
Diversified Test Mix
  Esoteric 36% of revenue
  Goal of 40% in 3  5 years
  Higher priced business
9
Competitive Position
Scale and Scope
  National infrastructure
  Broad test offering
  Managed care contracts
  Economies of scale
10
Primary LabCorp Testing Locations*
Esoteric Lab Locations
(CET, CMBP, Dianon, Esoterix, Monogram Biosciences, NGI, OTS, US Labs, Viromed)
Patient Service Centers*
Competitive Position
11
Standardized and
Efficient Processes
  Improved patient intake
  Automation of pre-analytics
  Capacity rationalization
  Logistics optimization
Scientific
Leadership
  Introduction of new tests
  Acquisitions and licensing
  Collaborations with leading
    companies and academic
    institutions
Competitive Position
12
2009 Priorities
13
Our Focus
  Gain new customers
  Maintain Price
  Control costs
  Implement Automation
  Advance leadership in                                      
      
personalized medicine
2009 Priorities
14
Gain New Customers
  Target specialty physicians
  Co-marketing with partners
    in science
  Appropriate promotion of
    specialty tests
2009 Priorities
Maintain Price
  Focus on high-value tests
  Promote outcomes improvement
  4.5% Medicare rate increase
  Managed care stability
15
Control Costs
  Renegotiate leases
  Review supply chain
  Contain discretionary expenses
  Control bad debt
  Continue to appropriately
    fund growth
2009 Priorities
16
Advance
Personalized
Medicine
  Increase esoteric testing
  Expand outcome improvement
    programs
  Develop and commercialize
    companion diagnostics
2009 Priorities
17
Increase
Esoteric Testing
  Introduction of new tests
  Acquisitions and licensing
  Collaborations with academic
    institutions
Advance Personalized Medicine
18
Expand Outcomes
Improvement
  Litholink kidney stone
  CKD
  Continual development of
    valuable programs
Advance Personalized Medicine
19
Advance Personalized Medicine
20
Develop
Companion Diagnostics
  Invest in clinical trials
  Relationships with biotech and     
    pharma companies
  Promote key tests
    (e.g., K-RAS, HLA-B* 5701,
    CYP 450)
Excellent Performance
21
Revenue and
EPS Growth
  10% Revenue CAGR
  17% EPS CAGR
(1) Excluding the $0.09 per diluted share impact in 2005 of restructuring and other special
charges, and a non-recurring investment loss; excluding the $0.06 per diluted share
impact in 2006 of restructuring and other special charges; excluding the $0.25 per
diluted share impact in 2007 of restructuring and other special charges; excluding the
$0.44 per diluted share impact in 2008 of restructuring and other special items
(2) EPS, as presented, represents adjusted, non-GAAP financial measures.  Diluted EPS,
as reported in the Company's Annual Report were:  $2.45 in 2004; $2.71 in 2005;
$3.24 in 2006; $3.93 in 2007; and $4.16 in 2008.
Excellent Performance
22
Leading Returns
Improving and leading returns   
Leading EBIT margin
Excellent Performance
23
Cash Flow
  10% OCF CAGR
  $2.5 B+ share repurchase
Third Quarter and YTD 2009 Results
24
2009
2008
+/(-)
2009
2008
+/(-)
Revenue
1,185.1
$
1,135.1
$     
4.4%
3,529.7
$
3,386.1
$
4.2%
Adjusted Operating Income  
237.6
$   
219.9
$        
8.0%
733.0
$   
717.2
$   
2.2%
Operating Income Margin  
20.0%
19.4%
60
      
bp
20.8%
21.2%
(40)
   
bp
Adjusted EPS  
1.22
$      
1.10
$           
10.9%
3.74
$      
3.48
$      
7.5%
Operating Cash Flow
246.4
$   
194.4
$        
26.7%
637.7
$   
565.6
$   
12.7%
Less: Capital Expenditures
(22.7)
$     
(41.5)
$         
-45.3%
(77.1)
$     
(120.4)
$  
-36.0%
Free Cash Flow
223.7
$   
152.9
$        
46.3%
560.6
$   
445.2
$   
25.9%
Nine Months Ended Sept 30,
Three Months Ended Sept 30,
Supplemental Financial Information
25
YTD
Q1 09
Q2 09
Q3 09
2009
Bad debt as a percentage of sales
5.3%
5.3%
5.3%
5.3%
Days sales outstanding
52
        
50
        
48
      
48
      
A/R coverage (Allowance for Doubtful Accts. / A/R)
19.5%
20.6%
21.9%
21.9%
Other Financial Information
September 30, 2009
($ in million's)
Key Points
  Critical position in health care delivery system
  Leadership in personalized medicine
  Stable pricing
  Well positioned to gain share
  Continued cost control
  Excellent cash flow
  Strong balance sheet
Conclusion
26
27
2009 LabCorp.   All rights reserved.   6967-0409


